Financial Disclosure Violations Are Unlikely To Warrant Clinical Holds – FDA
Executive Summary
Violations of FDA's financial disclosure requirements would be unlikely to lead to a clinical hold decision, FDA says in a draft guidance on investigator misconduct and clinical holds
You may also be interested in...
FDA Finalizes Guidance On Clinical Holds Due To Investigator Misconduct
FDA's final guidance on clinical holds due to clinical investigator misconduct drops some discussion of financial disclosure issues
FDA Finalizes Guidance On Clinical Holds Due To Investigator Misconduct
FDA's final guidance on clinical holds due to clinical investigator misconduct drops some discussion of financial disclosure issues
Next-Gen Smallpox, Anthrax Vaccines To Be First Use Of Animal Efficacy
A next-generation smallpox vaccine is expected to be the first product licensed under FDA's animal efficacy rule, HHS Office of the Assistant Secretary for Public Health Emergency Preparedness Senior Advisor Philip Russell, MD, said Aug. 28